Intuitive Surgical has led the robotic surgery market for more than 25 years with its da Vinci platform, the first system cleared in the U.S. in minimally invasive surgery. Since its initial launch, the company has introduced five major iterations, most recently rolling out advanced imaging and instrument controls to broaden its clinical applications. As of the third quarter, the installed base stood at 10,763 systems, up 13% year-over-year, underscoring steady hospital adoption in urology, gynecology, cardiothoracic and general surgery procedures.

Despite underperforming broader indices with an 8% gain in 2025, Intuitive Surgical’s high switching costs and extensive installed base create a formidable economic moat. Hospitals incur significant capital expenditure and staff training time to replace existing robots, reinforcing customer loyalty. The company also secures recurring revenue from consumable instruments and accessories, which are replaced after every procedure and carry higher gross margins, contributing to a gross margin of approximately 66%.

The global market for robotic-assisted surgery remains underpenetrated, with penetration rates below 15% in many regions. Intuitive Surgical recently obtained regulatory approval for three new surgical indications, expanding its addressable market. Analysts project double-digit revenue growth over the next decade as hospitals upgrade legacy systems and add new units. For long-term investors, a hypothetical $30,000 investment compounding at 12.4% annually could exceed $1 million over 30 years, illustrating the stock’s potential to serve as a core holding in a diversified portfolio.